Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population
Diana Norris, Louise Photiou, Mark Tacey, Con Dolianitis, George Varigos, Peter Foley, Chris Baker
JOURNAL OF DERMATOLOGICAL TREATMENT | TAYLOR & FRANCIS LTD | Published : 2017
BACKGROUND/OBJECTIVES: Psoriasis is a chronic condition that may require long-term treatment for disease control. This analysis utilizes data from the Australasian Psoriasis Registry with particular attention to the impact of biologic therapy on DLQI, and the differences between the biologics in terms of DLQI score change. METHODS: A retrospective review of patients enrolled in the Australasian Psoriasis Registry from April 2008 to August 2016 was conducted. All subjects from the registry that had DLQI and Psoriasis Assessment Severity Index (PASI) scores recorded at a baseline time point of treatment commencement, in addition to week 12 and 24 post commencement were included in the study. A..View full abstract
The authors acknowledge the Australasian Psoriasis Registry (Skin and Cancer Foundation Inc.) for provision of data and support of this project.